The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Selecting patients with MDS for allo-SCT in the era of post-transplant cyclophosphamide
Amy DeZern, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD, discusses patient selection for allogeneic stem cell transplantation (allo-SCT) in myelodysplastic syndromes (MDS) in the era of post-transplant cyclophosphamide (PTCy). Prof. DeZern highlights findings from BMT CTN 1102 (NCT02016781) and BMT CTN 1703 (NCT03959241), exploring how advances in graft-versus-host disease (GVHD) prophylaxis may influence transplant eligibility, timing, and outcomes, including in older and lower-risk patients. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
